Cygnal Therapeutics Inc. believes overlooked corners of neurobiology could unlock therapeutic strategies in cancer, inflammation and beyond. With $65 million from Flagship Pioneering and other undisclosed investors, the company launched Tuesday to advance two candidates...

A trio of gene editing industry veterans have teamed up to launch Korro Bio as their second company developing antisense-based therapies in less than a year. Korro is creating a new CRISPR-independent version of RNA...

Icosavax believes its computationally designed virus-like particles will open the clinically validated vaccine modality to a broader range of infectious diseases. The company expects its $51 million series A round, announced Thursday, to carry its...

Arcellx emerged from stealth with over $85 million in series B funding and a team of CAR T veterans to develop the latest iteration of a CAR T adaptor platform that balances safety and efficacy...

Veering from the field’s focus on neutralizing antibodies, X-Vax is developing vaccines that elicit non-neutralizing antibodies that direct the immune system to kill infected cells. Its lead candidate is in preclinical development to prevent HSV...

Chain Biotechnology’s engineered Clostridium -based therapies that are administered as dose-adjustable bacterial spores could offer more targeted delivery to the colon than other microbial therapies. “Most microbial activity in the GI tract occurs in the...

With a lead compound that staves off use-induced muscle damage, Edgewise thinks it can compete with dystrophin replacement therapies for muscular dystrophy. Edgewise Therapeutics emerged from stealth this month with a $50 million series B...

Flagship’s latest foray into white space technologies, Omega Therapeutics, is the newest company to tackle gene control by intervening at the 3-D chromatin structure level. With a platform that homes in on the structural elements...

With a $46.4 million series A round led by Arch Venture Partners and City Hill Ventures, Boundless Bio is opening up a new target space in cancer by combining a commercially explored concept in tumor...

Divide & Conquer aims to capitalize on new tumor biology that would prevent cancer cells from sharing resistance mechanisms and resensitize the tumor to chemo- and radiotherapy. Medicxi’s David Grainger founded the company in 2018...

With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immuno-oncology companies. Oncolytic viruses kill cancer cells by lysing the cells, and...

After bouncing around in several different companies, Peter Glazer’s peptide nucleic acid gene editing technology is getting another shot at development with the launch of Trucode. This time around, the technology is more advanced and...

Cullgen is expanding the toolbox of E3 ubiquitin ligases that can be used to target and degrade cancer-associated proteins by looking beyond widely used ligases. With its ubiquitin-mediated, small molecule-induced targeted elimination (uSMITE) technology, Cullgen...

Hesperos hopes to supplant animal models as the standard preclinical testing ground by designing reconfigurable, multi-organ chips to predict drug efficacy and toxicity early in development. The organ-on-a-chip company spun out of the Tissue Chip...

Tscan is screening TCRs against a genome-wide library of antigens to systematically identify novel cancer targets for T cell therapies that avoid off-target toxicities. "Most targets have been discovered in a one-off fashion, notably by...